Form 4: Cytek Biosciences COO Reports Stock Transactions

Paul Christopher Williams, COO of Cytek Biosciences, reports the vesting of restricted stock units and subsequent tax withholding, resulting in changes to his beneficial ownership of company stock.

Summary

• On May 20, 2024, Paul Christopher Williams, the Chief Operating Officer of Cytek Biosciences, engaged in transactions involving Cytek Biosciences, Inc. [CTKB] common stock and restricted stock units (RSUs).
• These transactions included the vesting of RSUs, the acquisition of common stock upon vesting, and the surrender of shares to cover tax withholding obligations.
• Specifically, 1,006, 613, and 5,893 RSUs vested, leading to the acquisition of corresponding shares of common stock.
• A total of 392 and 2,296 shares were withheld by the issuer to satisfy tax obligations at a price of $5.96 per share.
• Following these transactions, Williams' direct ownership includes 9,902 shares of common stock and 135,549 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to executive stock transactions, indicating a neutral sentiment.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC when company insiders, like the COO, trade in their company's stock. It provides transparency to the market regarding the transactions of company executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their executives.
• The vesting schedules described are typical for RSU grants.
• Tax withholding practices are consistent with standard compensation practices.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation and ownership changes.

Key Dates